Evaluation of Acute Locoregional Toxicity in Patients with Breast Cancer Treated with Adjuvant Radiotherapy in Combination with Pazopanib

Table 1

Patient characteristics.

Arm	Laterality	STAGE	CHEMO	Concurrent	SITE	RT Fields	RT DOSE
P-RT	R	III	AC-T + P	P	CW + Sclav	3	6000
P-RT	L	III	AC-T + P	P	CW + Sclav	3	6000
P-RT	L	III	AC-T + P	P	CW + Sclav	3	6000
P-RT	R	III	AC-T + P	P	Intact	2	6000
P-RT	R	III	AC-T + P	P	Intact + Sclav	3	6000
P-RT	R	III	AC-T + P	P	CW + Sclav	3	6000
P-RT	L	III	AC-T + P + H	P + Herceptin	Intact + Sclav + IM	3	6600
P-RT	R	III	AC-T + P	P	Intact + Sclav	3	6000
P-RT	L	III	AC-T + P + H	P + Herceptin	CW + Sclav	3	6000
P-RT	L	III	AC-T + P	P	CW + Sclav	3	6040
P-RT	L	III	AC-T + P	P	CW + Sclav and axilla	4	6000
P-RT	L	III	AC-T + P	P	CW + Sclav	3	6000
RT	R	IV	AC-T	//	CW + Sclav	3	6600
RT	L	III	AC-T + H	Herceptin	CW + Sclav	3	5800
RT	L	III	AC-T + H	Herceptin	CW + Sclav	3	6000
RT	R	III	AC-T	//	Intact + Sclav, IM, PAB/AAB	5	6000
RT	R	III	AC-T	//	Intact + Sclav	3	6000
RT	L	III	TC, TAC	//	CW + Sclav	3	6000
RT	L	III	AC-T + H	Herceptin	CW + Sclav	3	6000
RT	L	III	TC + H	Herceptin	CW + Sclav	3	6000
RT	L	III	AC-T + H	Herceptin	CW + Sclav	3	6000
RT	L	III	//	//	CW	2	6600
RT	R	III	AC-T	//	Intact	3	6000
RT	L	III	TC + H	Herceptin	CW + Sclav	3	6000
RT	L	III	AC	//	CW + Sclav	3	6000
RT	L	III	AC-T	//	CW + Sclav	3	6000
RT	L	III	//	//	CW + Sclav	3	6000
RT	L	III	TC + H	Herceptin	CW + Sclav	3	6000
RT	R	III	//	//	Intact + Sclav	3	6000
RT	R	III	ECF	//	CW + Sclav	3	6000
RT	L	III	AC-T + H	Herceptin	CW + Sclav	3	6000
RT	R	III	AC-T	//	Intact + Sclav	3	6000
RT	R	III	AC-T	//	Intact + Sclav	3	6000
RT	R	III	TC, TAC	//	CW + Sclav	3	6000
RT	L	III	AC-T + H	Herceptin	CW + Sclav	3	6000
RT	L	III	TC + H	Herceptin	CW + Sclav	3	6000
RT	L	III	AC-T + H	Herceptin	CW + Sclav	3	6000

Abbreviations: P: pazopanib; RT: radiotherapy; L: left; R: right; A: adriamycin; C: cytoxan; T: taxotere; H: herceptin; CW: chest wall; Sclav: supraclavicular; IM: internal mammary; PAB: posterior axillary boost; AAB: anterior axillary boost.